blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3526198

EP3526198 - 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.06.2021
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  10.07.2020
FormerGrant of patent is intended
Status updated on  17.03.2020
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe international publication has been made
Status updated on  20.04.2018
Formerunknown
Status updated on  03.11.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK, PT		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2019/34]
Inventor(s)01 / RICHTER, Jeremy M.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
02 / BATES, J. Alex
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
 [2019/34]
Representative(s)Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[2020/33]
Former [2019/34]Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6312 Steinhausen / CH
Application number, filing date17788068.912.10.2017
[2019/34]
WO2017US56265
Priority number, dateUS201662408272P14.10.2016         Original published format: US 201662408272 P
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018071622
Date:19.04.2018
Language:EN
[2018/16]
Type: A1 Application with search report 
No.:EP3526198
Date:21.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
[2019/34]
Type: B1 Patent specification 
No.:EP3526198
Date:12.08.2020
Language:EN
[2020/33]
Search report(s)International search report - published on:EP19.04.2018
ClassificationIPC:C07D213/74, C07D401/06, C07D401/14, C07D413/14, C07D401/04, C07D413/04, C07D417/04, C07D417/14, A61K31/4427, A61P9/00
[2019/34]
CPC:
C07D401/06 (EP,KR,US); C07D401/12 (US); A61K31/4427 (KR);
A61K31/4709 (KR); A61K31/55 (KR); A61K31/553 (KR);
A61P9/00 (EP,KR); A61P9/04 (EP); A61P9/10 (EP);
C07D213/74 (EP,KR,US); C07D401/04 (EP,KR,US); C07D401/14 (EP,KR,US);
C07D413/04 (EP,US); C07D413/14 (EP,KR,US); C07D417/04 (EP,KR,US);
C07D417/14 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA28.03.2019
MD28.03.2019
TitleGerman:3-SULFONYL-5-AMINOPYRIDIN-2,4-DIOL-APJ-AGONISTEN[2019/34]
English:3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS[2019/34]
French:AGONISTES D'APJ DE 3-SULFONYL-5-AMINOPYRIDINE -2,4-DIOL[2019/34]
Entry into regional phase28.03.2019National basic fee paid 
28.03.2019Designation fee(s) paid 
28.03.2019Examination fee paid 
Examination procedure28.03.2019Examination requested  [2019/34]
28.03.2019Date on which the examining division has become responsible
10.10.2019Amendment by applicant (claims and/or description)
18.03.2020Communication of intention to grant the patent
06.07.2020Fee for grant paid
06.07.2020Fee for publishing/printing paid
06.07.2020Receipt of the translation of the claim(s)
Opposition(s)14.05.2021No opposition filed within time limit [2021/29]
Fees paidRenewal fee
15.10.2019Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.10.2017
AL12.08.2020
AT12.08.2020
CY12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
MK12.08.2020
MT12.08.2020
NL12.08.2020
PL12.08.2020
PT12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
TR12.08.2020
IE12.10.2020
LU12.10.2020
BE31.10.2020
CH31.10.2020
LI31.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
[2022/33]
Former [2022/27]HU12.10.2017
AL12.08.2020
AT12.08.2020
CY12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
MT12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
TR12.08.2020
IE12.10.2020
LU12.10.2020
BE31.10.2020
CH31.10.2020
LI31.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/46]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
IE12.10.2020
LU12.10.2020
BE31.10.2020
CH31.10.2020
LI31.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/37]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
LU12.10.2020
BE31.10.2020
CH31.10.2020
LI31.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/36]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
LU12.10.2020
BE31.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/31]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MC12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SK12.08.2020
SM12.08.2020
LU12.10.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/28]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SK12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/25]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/23]AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/22]CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/21]DK12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/12]FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/10]FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/09]FI12.08.2020
LT12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
Former [2021/08]FI12.08.2020
LT12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
Former [2021/07]FI12.08.2020
LT12.08.2020
NO12.11.2020
Cited inInternational search[A]WO2015188073  (RES TRIANGLE INST [US], et al) [A] 1-15 * page 1 * * example - * * claim - *;
 [AP]WO2016196771  (BRISTOL MYERS SQUIBB CO [US]) [AP] 1-15 * example - ** claim - *;
 [AP]WO2017066402  (BRISTOL MYERS SQUIBB CO [US]) [AP] 1-15 * abstract * * example - * * claim - *;
 [A]  - CAO JIANGANG ET AL, "Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases", CURRENT DRUG TAR, BENTHAM SCIENCE PUBLISHER, US, (20150201), vol. 16, no. 2, ISSN 1389-4501, pages 148 - 155, XP009191040 [A] 1-15 * abstract * * page 152; figure 3 *
by applicant   - ROGER, V.L. et al., Circulation, (20120000), vol. 125, no. 1, pages e2 - e220
    - ROGER, V.L. et al., JAMA, (20040000), vol. 292, no. 3, pages 344 - 350
    - BORLAUG, B.A. et al., Eur. Heart J., (20110000), vol. 32, no. 6, pages 670 - 679
    - JAPP, A.G. et al., Biochem. Pharmacol., (20080000), vol. 75, no. 10, pages 1882 - 1892
    - CHARO, D.N. et al., Am. J. Physiol. Heart Circ. Physiol., (20090000), vol. 297, no. 5, pages H1904 - H1913
    - KUBA, K. et al., Cire. Res., (20070000), vol. 101, no. 4, pages e32 - 42
    - BERRY, M.F., Circulation, (20040000), vol. 110, no. 1, pages II1187 - II193
    - ASHLEY, E.A., Cardiovasc. Res., (20050000), vol. 65, no. 1, pages 73 - 82
    - CHENG, X. et al., Eur. J. Pharmacol., (20030000), vol. 470, no. 3, pages 171 - 175
    - JAPP, A.G. et al., Circulation, (20100000), vol. 121, no. 16, pages 1818 - 1827
    - TATEMOTO, K., Regul. Pept., (20010000), vol. 99, no. 2-3, pages 87 - 92
    - SIMPKIN, J.C., Basic Res. Cardiol, (20070000), vol. 102, no. 6, pages 518 - 528
    - SIDDIQUEE, K. et al., J. Hypertens., (20110000), vol. 29, no. 4, pages 724 - 731
    - SCIMIA, M.C. et al., Nature, (20120000), vol. 488, no. 7411, pages 394 - 398
    - KOGUCHI, W. et al., Circ. J., (20120000), vol. 76, no. 1, pages 137 - 144
    - SARZANI, R. et al., J. Card. Fail., (20070000), vol. 13, no. 7, pages 521 - 529
    - The Peptides: Analysis, Synthesis, Biology, Academic Press, (19810000), vol. 3
    - Methods in Enzymology, Academic Press, (19850000), vol. 112, pages 309 - 396
    - "Design and Application of Prodrugs", BUNDGAARD, H. et al., A Textbook of Drug Design and Development, Harwood Academic Publishers, (19910000), pages 113 - 191
    - BUNDGAARD, H., Adv. Drug Deliv. Rev., (19920000), vol. 8, pages 1 - 38
    - BUNDGAARD, H. et al., J. Pharm. Sci., (19880000), vol. 77, page 285
    - KAKEYA, N. et al., Chem. Pharm. Bull., (19840000), vol. 32, page 692
    - Prodrugs and Targeted Delivery (Methods and Principles in Medicinal Chemistry), Wiley-VCH, (20110000), vol. 47
    - PITKIN, S.L. et al., Pharmacol. Rev., (20100000), vol. 62, no. 3, pages 331 - 342
    - KLEINZ, J.M et al., Pharmacol. Iher., (20050000), vol. 107, no. 2, pages 198 - 211
    - TATEMOTO, K. et al., Biochem. Biophys. Res. Commun., (19980000), vol. 255, pages 471 - 476
    - MAGUIRE, J.J. et al., Hypertension, (20090000), vol. 54, no. 3, pages 598 - 604
    - KLEINZ, J.M. et al., Pharmacol. Ther., (20050000), vol. 107, no. 2, pages 198 - 211
    - CHUN, A.J. et al., J Clin. Invest., (20080000), vol. 118, no. 10, pages 3343 - 3354
    - ALLEN, JR., L.V. et al., Remington: The Science and Practice of Pharmacy, Pharmaceutical Press, (20120000), vol. 2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.